ǰÑÔ
Ô·¢ÐԸΰ©(primary liver cancer)ÊÇÌìϹæÄ£ÄÚéæÃüÂÊ×î¸ßµÄ¶ñÐÔÖ×ÁöÖ®Ò»¡£ÎÒ¹úÊǸΰ©·¢²¡ÂʽϸߵĹú¼ÒÖ®Ò»£¬Æä·¢²¡ÂʾÓÎÒ¹ú¶ñÐÔÖ×Áö·¢²¡Âʵĵڶþλ¡£Ô·¢ÐԸΰ©ÖÐ95£¥ÊôÓÚ¸Îϸ°û¸Î°©(hepatocellular carcinoma,HCC)ÊÇÓÉ»¯Ñ§Ö°©Îï¡¢²¡¶¾µÈ¶àÖÖÒòËØÒýÆðµÄ¸Îϸ°ûÉú³¤Ê§¿Ø¶øµ¼Öµİ©±ä£¬Óë¶àÖÖ»ùÒòµÄµ÷¿ØºÍ±í´ïÇ×½üÏà¹Ø¡£ÏÖÔÚ£¬¸Î°©µÄÖ²¡»úÖÆÉÐδÑо¿ÇåÎú£¬Ëæ×ŶԸΰ©¶¯ÎïÄ£×ÓÑо¿µÄһֱ̽Ë÷£¬ÒѾ½¨ÉèÁË×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔ¡¢ÝªÖ²ÐÔ¼°×ª»ùÒò¶¯Îï¸Î°©Ä£×Ó¡£ÓÉÓÚÕâЩģ×ӽϺõØÄ£ÄâÁËÈËÀà¸Î°©£¬Òò¶ø¿ÉÓÃÓڸΰ©µÄÐÄÀí¡¢Ï¸°ûºÍ·Ö×ӵȷ¢²¡»úÖÆ·½ÃæµÄÑо¿£¬Ò²¿ÉÓÃÓڸΰ©ÖÎÁÆÒ©ÎïµÄɸѡÒÔ¼°»ùÒòÖÎÁƵÄ̽Ë÷¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÓÕ·¢ÐԸΰ©¶¯ÎïÄ£×ÓÊÇÖ¸Óû¯Ñ§¡¢ÎïÀí¼°ÉúÎïÖ°©ÒòËØ×÷ÓÃÓÚʵÑ鶯ÎģÄâ¸ÎËðÉË£ÏËά»¯£¶ñÐÔת»¯µÄÖÜÆÚת±ä£¬ÓÕ·¢¶¯ÎïÐγɵĸΰ©¡£ÏÖÔÚÒÔ»¯Ñ§ÓÕ°©¼ÁÓÕ·¢ÎªÖ÷£¬³£ÓÃÖ¸ΰ©µÄÎïÖÊÓжþÒÒ»ùÑÇÏõ°·(diethylnitrosamine,DEN)¡¢¶Ô¶þ¼×»ù°±»ùżµª±½(dimethylaminoazobenzene,OBA)¡¢2-ÒÒËá°±»ùËá(2-acetylamino fluorine,2-AAF)¡¢Ñǰ±»ùżµª¼×±½(o-aminoazotolueue,OAT)ºÍ»ÆÇúÃ¹ËØ(aflatoxin,AF)¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
DENÓÕµ¼Ä£×Ó£ºµ¥ÓÃʱ¿É¸øÓèSprague Dawley´óÊó»òWistar´óÊó0.25£¥DENË®ÈÜÒº°´10mg/kg¼ÁÁ¿¹àθ£¬Ã¿ÖÜÒ»´Î£¬Í¬Ê±ÌìÌìÒÔ0.025£¥DENË®ÈÜÒº¹©¶¯ÎïÒûÓã¬Ò»Á¬Î¹Ñø6¸öÔ¡£»ò¸øÓèÒ»´ÎÐÔ¸¹Ç»×¢Éä0.5£¥DENµÄÎÞ¾úË®ÈÜÒº(100mg/kg), 1Öܺó×îÏÈÒ»Á¬¹©Ó¦100mg/LµÄDENÎÞ¾úË®ÈÜÒº×ÔÓÉÒûÓÃÖ±ÖÁ16ÖÜ£»Æä¼äµÚ9~11ÖܸũӦÎÞ¾úË®¡£DENÒà¿ÉÁªÓÃ2-AAF¼´Solt-FarberÓÕ°©·¨£ºÒ»´ÎÐÔ¸øÓè´óÊó¸¹Ç»×¢Éä200mg/kg DENÈÜÒº£¬2ÖܺóÎ¹Ñøº¬0.02£¥2-AAFËÇÁÏ14Ì죬µÚ3ÖÜÐд󲿷ָÎÇгý£¬µÚ4Öָܻ´Í¨Ë×ËÇÁÏÎ¹Ñø¡£
DBAÓÕµ¼Ä£×Ó£º¼´Óú¬0.06£¥DABËÇÁÏÎ¹Ñø£¬²¢¿ØÖÆÎ¬ÉúËØB2º¬Á¿(≤1.5~2.0mg/kg)£¬Ò»Á¬Î¹Ñø4~6¸öÔ¡£
2-AAFÓÕµ¼Ä£×Ó£ºº¬ÓÐ0.05£¥2-AAFËÇÁÏÎ¹ÑøSprague Dawley´óÊó£¬Ò»Á¬3~4¸öÔ¡£
OATÓÕµ¼Ä£×Ó£ºÓú¬1£¥OATÈÜÒº(10mg/ml)Í¿ÔÚСÊóµÄÁ½¼çëÎ¼äÆ¤·ôÉÏ£¬¸ôÈÕ1´Î£¬Ã¿´Î2~3µÎ£¬Ò»Á¬7~8ÖÜ¡£
AFÓÕµ¼Ä£×Ó£º´óÊó¸Î°©Ã¿ÔÂËÇÁÏÖк¬0.001~0.015ppmι6¸öÔ¡£»òÓöþ¼×»ùÑÇí¿(DMSO)ÏûÈÚAF£¬°´ÌìÌì400µg/kg¸¹Ç»×¢Éä1´Î£¬Ò»Á¬2Öܺó×èÖ¹×¢É䣬һ´ÎÐÔÔÙ×¢Éä0.75~1.50mg/kgµÄAF£¬2ÖܺóÐиδ󲿷ÖÇгýÊõ¡£
¡¾Ä£×ÓÌØµã¡¿£º
DENΪ×î³£¼ûµÄ»¯Ñ§ÓÕ°©¼Á£¬ÓÕ·¢´óÊóÖ°©ÂÊΪ80£¥¡£DBA·¨6¸öÔ¼´¿É±¬·¢¸Î°©£¬ÓÕ°©ÂÊΪ60£¥¡£2-AAFÓÕµ¼3Öܼ´¿É·ºÆð°©Ç°²¡±ä£¬¾µÏ¼û¸Îϸ°û³ÊÂÑÔ²ÐÎϸ°ûÔöÉú£¬ÇҾ߾Þϸ²»µÈµÄ°©³²½á½Ú£¬3¡«4¸öÔºóÓÐ80£¥~90£¥¶¯Îﱬ·¢¸ÎÖ×Áö¡£OATͿĨ·¨¸øÒ©ºó8Öܼ´·ºÆð½á½Ú£¬7¸öÔºó¼´ÓÕ·¢Ð¡Êó¸Î°©£¬ÓÕ°©ÂÊΪ50£¥×óÓÒ¡£AFÓÕ·¢´óÊó¸Î°©±¬·¢ÂÊΪ80%£¬µ«²¡³Ì½Ï³¤£¬Ö×Áö¶àΪÃÖÂþ½á½ÚÐÍ¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
ÓÕ·¢ÐÔÄ£×ÓÆð²¡ÒþÄä¡¢ÓÕµ¼ÖÜÆÚ³¤¡£ÓÕµ¼Àú³ÌÖж¯ÎïµÄéæÃüÂʽϸߣ¬¸Î°©±¬·¢µÄ²¿Î»¡¢²¡ÔîÊýʵʱ¼äµÈ¸öÌå²î±ðÒ²½Ï´ó¡£ÏÖÔÚ£¬¸ÃÄ£×Ó¶àÓÃÓڸΰ©²¡Òòѧ¡¢ÒÅ´«Ñ§¼°ÉúÎïѧµÈ·½ÃæµÄÑо¿¡£
²Î¿¼ÎÄÏ×£º
1.³Â»ª£¬ÕÔµÂÃ÷. ¸Î°©¶¯ÎïÄ£×Ó£®ÊµÑ鶯Îïѧ¿ÆÓëÖÎÀí£¬2005,22 (4):32-35
2.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000
3.Å˶أ¬ÕÅäø£¬Àî×Ú·¼£¬µÈ£®¶þÒÒ»ùÑÇÏõ°·ÓÕ·¢´óÊó¸Î°©Àú³ÌÖÐÆ¢Ôà¾ÞÊÉϸ°ûµÄת±ä£®ÖлªÊµÑéÍâ¿ÆÔÓÖ¾£¬2009, 26 (5):588-591
4.Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol, 2013, 7 (2):206-223
5.Newell P, Villanueva A,Friedman SL, et al. Experimental models of hepatocellular carcinoma. J Hepatol, 2008, 48(5):858-879
6.Sonoda A, Nitta N, Nitta-Seko A, el al. Time-coursestudies of implanted rabbit VX2 liver tumors to identify the appropriate time for starting hepatic arterial emholization in animal models. Oncology, 2011, 80 (1-2):92-96